Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Blood (2019) 134 (Supplement_1): 469.

https://doi.org/10.1182/blood-2019-123367

Published: 2019

Journal Articles

Droplet Digital PCR Reliably Detects a Single Copy of BCR-ABL1

Jaspal Kaeda, PhD FRCPath, Simone Bonecker, Frauke Ringel, Michaela Schwarz, Bernd Dörken, Ilana Zalcberg, Philipp Le Coutre, MD

Blood (2015) 126 (23): 2784.

https://doi.org/10.1182/blood.V126.23.2784.2784

Published: 2015

Journal Articles

Long-Term Follow-up of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients After Stem Cell Mobilisation Under Imatinib.

Theo D. Kim, MD, Michaela Schwarz, MD, Karl-Anton Kreuzer, MD, Jaspal Kaeda, PhD, Kamran Movassaghi, MD, Peggy Grille, Peter Daniel, MD, PhD, Bernd Dörken, Philipp le Coutre

Blood (2010) 116 (21): 3418.

https://doi.org/10.1182/blood.V116.21.3418.3418

Published: 2010

Journal Articles

Sequence Analysis of MPL Exon 10 of ET and MF JAK2 V617F Negative Patients Reveals a New Mutation

Celeste Bento, Marta Duarte, Helena Almeida, Cristina Menezes, Alexandra Estevinho, Margarida Coucelo, Jaspal Kaeda, Maria Leticia Ribeiro, MD, PhD

Blood (2008) 112 (11): 5254.

https://doi.org/10.1182/blood.V112.11.5254.5254

Published: 2008

Journal Articles

For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance.

Hugues de Lavallade, MD, Jamshid S. Khorashad, MD, Dragana Milojkovic, MD, Simon Wagner, PhD, Jaspal Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 323.

https://doi.org/10.1182/blood.V110.11.323.323

Published: 2007

Journal Articles

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

Hugues de Lavallade, MD, Dragana Milojkovic, MD, Jamshid S. Khorashad, MD, Alistair Reid, PhD, Eduardo Olavarria, MD, Jaspal Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 1045.

https://doi.org/10.1182/blood.V110.11.1045.1045

Published: 2007

Journal Articles

A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.

Nicholas Heaney, Mark Drummond, Jaspal Kaeda, Franck Nicolini, Richard Clark, George Wilson, Pat Shepherd, Jane Tighe, Lorna McLintock, Timothy Hughes, Tessa L. Holyoake

Blood (2007) 110 (11): 1033.

https://doi.org/10.1182/blood.V110.11.1033.1033

Published: 2007

Journal Articles

Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2 nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1 st Line IM Patients.

Jaspal Kaeda, Andreas Hochhaus, Jerald Radich, Susan Branford, Charlene So, Insa Gathmann, Elisabeth Wehrle, John Goldman, Timothy Hughes, on Behalf of IRIS Study Group

Blood (2006) 108 (11): 2139.

https://doi.org/10.1182/blood.V108.11.2139.2139

Published: 2006

Journal Articles

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Blood (2006) 108 (1): 28–37.

https://doi.org/10.1182/blood-2006-01-0092

Published: 2006

Journal Articles

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy

Jaspal Kaeda, Derville O'Shea, Richard M. Szydlo, Eduardo Olavarria, Francesco Dazzi, David Marin, Susan Saunders, Jamshid S. Khorashad, Nicholas C. P. Cross, John M. Goldman, Jane F. Apperley

Blood (2006) 107 (10): 4171–4176.

https://doi.org/10.1182/blood-2005-08-3320

Published: 2006

Journal Articles

Use of Direct Sequence PCR for ABl Kinase Mutations in Patients with CML Blast Crisis, Treated Prior to the Availability of Imatinib Therapy.

Sara Ghorashian, MD, Anna Babb, MD, Jamshid Khorasan, MD, Jaspal Kaeda, PhD, David Marin, MD, Jane Apperley, MD, PhD

Blood (2005) 106 (11): 2002.

https://doi.org/10.1182/blood.V106.11.2002.2002

Published: 2005

Journal Articles

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

John M. Goldman, MD, Timothy Hughes, MD, Jerry Radich, MD, Susan Branford, PhD, Andreas Hochhaus, MD, Charlene So, PharmD, Insa Gathmann, MS, Elisabeth Wehrle, Jaspal Kaeda, PhD

Blood (2005) 106 (11): 163.

https://doi.org/10.1182/blood.V106.11.163.163

Published: 2005

Journal Articles

Circulating Human Fetal Mesenchymal Stem Cells Support Ltc-Ic and Express a Cytokine Profile To Maintain Quiescence of Co-Circulating Hemopoietic Stem Cells Circulating Human Fetal Mesenchymal Stem Cells Support LTC-IC and Express a Cytokine Profile To Maintain Quiescence of Co-Circulating Hemopoietic Stem Cells.

Josu de la Fuente, MRCP, Jerry Chan, MBBS, Keelin O’Donoghue, MRCOG, Jaspal Kaeda, PhD, Sailesh Kumar, PhD, Nicholas M. Fisk, PhD, Irene A.G. Roberts, MD

Blood (2004) 104 (11): 2327.

https://doi.org/10.1182/blood.V104.11.2327.2327

Published: 2004

Journal Articles

Cyclin-C: Analysis of a Candidate Tumour Suppressor Genes on 6q15-q21 in Malignant Lymphoid Cell Lines and Lymphoid Acute Leukemias.

Paul B. Sinclair, PhD, Wayne Mitchell, PhD, Jaspal Kaeda, PhD, Letizia Foroni, MD, PhD

Blood (2004) 104 (11): 4332.

https://doi.org/10.1182/blood.V104.11.4332.4332

Published: 2004

Journal Articles

Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib

Feng Lin, Mark Drummond, Stephen O'Brien, Francisco Cervantes, John Goldman, Jaspal Kaeda

Blood (2003) 102 (3): 1143.

https://doi.org/10.1182/blood-2002-12-3916

Published: 2003

Journal Articles

Monitoring CML after nonmyeloablative transplantations: how negative is negative?

Jaspal Kaeda, Jane Apperley, Junia Melo, Nicolas Cross, John Goldman

Blood (2003) 101 (12): 5084–5085.

https://doi.org/10.1182/blood-2003-01-0086

Published: 2003

Journal Articles

Early detection of BCR-ABL transcripts by quantitative reverse transcriptase–polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia

Eduardo Olavarria, Edward Kanfer, Richard Szydlo, Jaspal Kaeda, Katayoun Rezvani, Kate Cwynarski, Christopher Pocock, Francesco Dazzi, Charles Craddock, Jane F. Apperley, Nicholas C. P. Cross, John M. Goldman

Blood (2001) 97 (6): 1560–1565.

https://doi.org/10.1182/blood.V97.6.1560

Published: 2001

Journal Articles

Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

Francesco Dazzi, Richard M. Szydlo, Nicholas C. P. Cross, Charles Craddock, Jaspal Kaeda, Ed Kanfer, Kate Cwynarski, Eduardo Olavarria, Agnes Yong, Jane F. Apperley, John M. Goldman

Blood (2000) 96 (8): 2712–2716.

https://doi.org/10.1182/blood.V96.8.2712

Published: 2000

Journal Articles

Absence of host-derived cells in the blood of patients in remission after allografting for chronic myeloid leukemia

Andrew Chase, Sally Parker, Jaspal Kaeda, Renuka Sivalingam, Nicholas C. P. Cross, John M. Goldman

Blood (2000) 96 (2): 777–778.

https://doi.org/10.1182/blood.V96.2.777

Published: 2000

Journal Articles

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

Andreas Hochhaus, Andreas Reiter, Susanne Saußele, Anja Reichert, Michael Emig, Jaspal Kaeda, Beate Schultheis, Ute Berger, Patricia C. A. Shepherd, Norman C. Allan, Rüdiger Hehlmann, John M. Goldman, Nicholas C. P. Cross

Blood (2000) 95 (1): 62–66.

https://doi.org/10.1182/blood.V95.1.62

Published: 2000

NARROW

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Droplet Digital PCR Reliably Detects a Single Copy of BCR-ABL1

Long-Term Follow-up of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients After Stem Cell Mobilisation Under Imatinib.

Sequence Analysis of MPL Exon 10 of ET and MF JAK2 V617F Negative Patients Reveals a New Mutation

For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance.

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.

Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2 nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1 st Line IM Patients.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy

Use of Direct Sequence PCR for ABl Kinase Mutations in Patients with CML Blast Crisis, Treated Prior to the Availability of Imatinib Therapy.

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

Cyclin-C: Analysis of a Candidate Tumour Suppressor Genes on 6q15-q21 in Malignant Lymphoid Cell Lines and Lymphoid Acute Leukemias.

Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib

Monitoring CML after nonmyeloablative transplantations: how negative is negative?

Early detection of BCR-ABL transcripts by quantitative reverse transcriptase–polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia

Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

Absence of host-derived cells in the blood of patients in remission after allografting for chronic myeloid leukemia

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only